



Gerstner Sloan Kettering
Graduate School of Biomedical Sciences

[Welcome to GSK](#)

HUMAN ONCOLOGY & PATHOGENESIS PROGRAM

[Admissions](#)

The Ping Chi Lab

[Cancer Biology](#)

Research

[Cancer Engineering](#)

[Research](#)


[Alumni](#)



Ping Chi, MD, PhD

It is well recognized that the cellular context contributes to susceptibility to oncogenic transformation mediated by different “driver” oncogenes. The focus of our laboratory is to discover and understand the critical genetic and epigenetic factors that determine the cellular-context-dependent oncogenesis in distinct cancer types, with a primary focus on sarcoma and melanoma. We use multimodality approaches, including transcriptome analyses, epigenome mapping, and gene-expression-based high-throughput screens, as well as murine models to understand the mechanisms of pathogenesis and to develop biomarkers and targeted therapies based on insight into disease pathogenesis.

[View Lab Overview \(https://www.sloankettering.edu/research-areas/labs/ping-chi/overview\)](https://www.sloankettering.edu/research-areas/labs/ping-chi/overview)



Featured News


EVENT



[2017 MSK Convocation and Commencement Ceremony Celebrates Distinguished Scientists and Young Scholars](#)

Degrees were presented and awards were given at the 38th annual ceremony held on May 18.

IN THE LAB



[Molecular Studies Provide New Clues about Rare Soft Tissue Sarcoma](#)

Genetic analysis reveals biomarkers and possible drug targets for malignant peripheral nerve sheath tumors.

ANNOUNCEMENT



[Geoffrey Beene Rock Stars of Science™ Campaign Features Memorial Sloan Kettering Researchers](#)

The initiative, focused on investigators from Memorial Sloan Kettering's Geoffrey Beene Cancer Research Center, highlights the critical need for funding scientific research.

[View All Featured News](#)

Publications Highlights

Patel AJ, Warda S, Maag JLV, Misra R, Miranda-Roman MA, Pachai MR, Lee CJ, Li D, Wang N, Bayshtok G, Fishinevich E, Meng Y, Wong EWP, Yan J, Giff E, Pappalardi MB, McCabe MT, Fletcher JA, Rudin CM, Chandarlapaty S, Scandura JM, Koche RP, Glass JL, Antonescu CR, Zheng D, Chen Y*, Chi P*. [PRC2 Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1 Targeted Therapy via Enhanced Viral Mimicry.](#) Cancer Discovery. 2022 Jul 5;cd.21.1671. doi: 10.1158/2159-8290.CD-21-1671. Online ahead of print. PMID: 35789380; Featured in "In the Spotlight".

Yan J, Chen Y, Patel AJ, Warda S, Lee CJ, Nixon BG, Wong EWP, Miranda-Román MA, Yang N, Wang Y, Pachai MR, Sher J, Giff E, Tang F, Khurana E, Singer S, Liu Y, Galbo PM Jr, Maag JL, Koche RP, Zheng D, Antonescu C, Deng L, Li M, Chen Y*, Chi P*. *Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic therapeutic viruses.* Journal of Clinical Investigation. 2022 Jul 19:e153437. doi: 10.1172/JCI153437. Epub ahead of print. PMID: 35852856.

Chi P*, Qin LX, Nguyen B, Kelly CM, D'Angelo SP, Dickson MA, Gounder MM, Keohan ML, Movva S, Nacev BA, Rosenbaum E, Thornton KA, Crago AM, Yoon S, Ulaner G, Yeh R, Martindale M, Phelan HT, Biniakewitz MD, Warda S, Lee CJ, Berger MF, Schultz ND, Singer S, Hwang S, Chen Y, Antonescu CR, Tap WD. [Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor.](#) Journal of Clinical Oncology. 2022;40(9):997-1008. PMID: 358937014.

Chi P*, Qin LX, Camacho N, Kelly CM, D'Angelo SP, Dickson MA, Gounder MM, Keohan ML, Movva S, Nacev BA, Rosenbaum E, Thornton KA, Crago AM, Francis JH, Martindale M, Phelan HT, Biniakewitz MD, Lee CJ, Singer S, Hwang S, Berger MF, Chen Y, Antonescu CR, Tap WD*. [Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors.](#) Clinical Cancer Research. 2022;28(8):1507-1517. PMID: 359012681.

Tang F, Xu D, Wang S, Wong CK, Martinez-Fundichely A, Lee CJ, Cohen S, Park J, Hill CE, Eng K, Bareja R, Han T, Liu EM, Palladino A, Di W, Gao D, Abida W, Beg S, Puca L, Meneses M, de Stanchina E, Berger MF, Gopalan A, Dow LE, Mosquera JM, Beltran H,

Sternberg CN, Chi P, Scher HI, Sboner A, Chen Y, Khurana E. [Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets.](#)
Science. 2022; 376(6596):eabe1505. PMCID: PMC9299269.

[View All Publications](#)

People

A portrait of Ping Chi, MD, PhD, a woman with dark hair, wearing a light blue and white striped sleeveless top, with her arms crossed. The background is a blurred indoor setting.

Ping Chi, MD, PhD
Co-Director, Sarcoma Translational Research, MSK Sarcoma Center
Professor

- Physician-scientist Ping Chi studies genetic and epigenetic mechanisms of transcriptional regulation by oncogenic factors in GIST, MPNST, melanoma and other solid tumors.
- MD, Weill Cornell Medical College
- PhD, The Rockefeller University

[View physician profile](#)
Physician profile

Members

Yudi Bao
Research Associate




Woo Hyun (Alex) Cho
Research Technician

Zoe Jacobs
Research Technician Lab
Kyle Kristoff
Alumni
Research Technician
Marion Liu
Assistant Attending, Surgery Lab Affiliations



Sarah Qadir
Laboratory Administrator


Alina Teuber
Research Scholar



Elissa Wai Pung Wong
Scientific Research Lead



Juan Yan
Senior Research Scientist



Yang Zeng
Research Scholar

Yang Zeng
Research Scholar
Jiasheng Zhou
Data Analyst



Tao Zhang
Research Associate

Achievements

- Kimmel Scholar Award, Sidney Kimmel Foundation (2012)
- Research Grant, Sarcoma Foundation of America (2012)
- Grant, GIST Cancer Awareness Foundation (2012)
- Director's New Innovator Award, National Institutes of Health (2012)
- Clinical Scientist Development Award, National Institutes of Health (2011)

Lab News & Events

UPCOMING EVENT

[Transposable Elements and Cancer Epigenome Evolution](#)

Tuesday, June 9, 2026 - 1:30 PM to 2:30 PM

Memorial Sloan Kettering Cancer Center
Rockefeller Research Laboratories
430 East 67th Street
Room RRL-116
New York, NY 10065

[Zoom](#)

Open Positions

To learn more about available postdoctoral opportunities, please visit our [Career Center](#)

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit [Resources for Postdocs](#)

Career Opportunities

[Apply now](https://www.sloankettering.edu/research-areas/labs/ping-chi/career-opportunities) (<https://www.sloankettering.edu/research-areas/labs/ping-chi/career-opportunities>)

Get in Touch

 [646-888-3349](tel:646-888-3349)

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Ping Chi discloses the following relationships and financial interests:

- **Boxer Capital, LLC**
Professional Services and Activities
- **Chinese Institutes for Medical Research (CIMR)**
Professional Services and Activities (Uncompensated)
- **Deciphera**
Professional Services and Activities
- **Ningbo NewBay Medical Technology Co., Ltd.**
Professional Services and Activities
- **Peking University**
Professional Services and Activities
- **Peking University People's Hospital**
Professional Services and Activities

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1,

2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies [here](#) . For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at ecoi@mskcc.org .

[View all disclosures \(https://www.sloankettering.edu/disclosures\)](https://www.sloankettering.edu/disclosures)

© 2025 Louis V. Gerstner Jr. Graduate School of Biomedical Sciences Memorial Sloan Kettering Cancer Center